Search hospitals > California > Los Angeles
David Geffen School of Medicine at UCLA
Claim this profileLos Angeles, California 90095
Global Leader in Human Immunodeficiency Virus Infection
Global Leader in High Blood Pressure
Conducts research for Pulmonary Hypertension
Conducts research for Pulmonary Arterial Hypertension
Conducts research for Fibrosis
232 reported clinical trials
9 medical researchers
Summary
David Geffen School of Medicine at UCLA is a medical facility located in Los Angeles, California. This center is recognized for care of Human Immunodeficiency Virus Infection, High Blood Pressure, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Fibrosis and other specialties. David Geffen School of Medicine at UCLA is involved with conducting 232 clinical trials across 283 conditions. There are 9 research doctors associated with this hospital, such as Gary Schiller, MD, Perry Shieh, MD, PhD, Jaime G Deville, M.D., and Shaun Hussain.Area of expertise
1Human Immunodeficiency Virus Infection
Global LeaderARV
HIV infection positive
Stage I
2High Blood Pressure
Global LeaderTop PIs
Gary Schiller, MDUCLA Medical Center6 years of reported clinical research
Expert in Acute Myeloid Leukemia
Expert in Leukemia
30 reported clinical trials
52 drugs studied
Perry Shieh, MD, PhDDavid Geffen School of Medicine at UCLA1 year of reported clinical research
Studies Muscular Dystrophy
Studies Duchenne Muscular Dystrophy
15 reported clinical trials
16 drugs studied
Jaime G Deville, M.D.David Geffen School of Medicine at UCLA (CRS 5112)3 years of reported clinical research
Studies Human Immunodeficiency Virus Infection
Studies Coronavirus
7 reported clinical trials
11 drugs studied
Shaun HussainDavid Geffen School of Medicine at UCLA2 years of reported clinical research
Studies Syndrome
Studies Dravet Syndrome
4 reported clinical trials
3 drugs studied
Clinical Trials running at David Geffen School of Medicine at UCLA
Lymphoma
Pulmonary Arterial Hypertension
Non-Hodgkin's Lymphoma
Interstitial Lung Disease
Alpha-1 Antitrypsin Deficiency
Diffuse Large B-Cell Lymphoma
B-Cell Lymphoma
High Blood Pressure
Pulmonary Hypertension
Lennox Gastaut Syndrome
Epcoritamab Combinations
for Non-Hodgkin's Lymphoma
This study is evaluating whether a drug called epcoritamab can be used to treat blood cancers.
Recruiting3 awards Phase 1 & 26 criteria
Odronextamab + Chemotherapy
for B-Cell Lymphoma
This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with diffuse large B-cell lymphoma (DLBCL) that have not been treated before (called "previously untreated"), have come back after treatment (called "relapsed"), or have not responded to treatment (called "refractory"). This study will be made up of Part 1a, Part 1b, and Part 2.The aim of Part 1a and Part 1b of the study is to see how safe and tolerable the study drug in combination with chemotherapy is and to determine the dose and schedule of the study drug to be combined with chemotherapy in Part 2 of the study. The aim of Part 2 of the study is to see how effective the combination of the study drug with chemotherapy is in comparison with the combination of rituximab and chemotherapy, the current standard of care treatment approved for Non-Hodgkin's lymphoma (NHL). Standard of care means the usual medication expected and used when receiving treatment for a condition. The study is looking at several other research questions, including: What side effects may happen from taking the study drug when combined with chemotherapy How much study drug is in your blood at different times Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) The impact from the study drug on your quality of life and ability to complete routine daily activities
Recruiting2 awards Phase 36 criteria
Epcoritamab
for Chronic Lymphocytic Leukemia
This study is evaluating whether a drug may help treat chronic lymphocytic leukemia.
Recruiting1 award Phase 1 & 213 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at David Geffen School of Medicine at UCLA?
David Geffen School of Medicine at UCLA is a medical facility located in Los Angeles, California. This center is recognized for care of Human Immunodeficiency Virus Infection, High Blood Pressure, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Fibrosis and other specialties. David Geffen School of Medicine at UCLA is involved with conducting 232 clinical trials across 283 conditions. There are 9 research doctors associated with this hospital, such as Gary Schiller, MD, Perry Shieh, MD, PhD, Jaime G Deville, M.D., and Shaun Hussain.